Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Martin Vogelbaum
AddedMar 31, 2024
UpdatedMay 31, 2026
Martin Vogelbaum

Martin Vogelbaum

Board Member, Cara Therapeutics

Crunchbase

Martin Vogelbaum's Career

Cara Therapeutics
Cara Therapeutics

Stamford, CT, US

Board Member· Board
Ajax Therapeutics
Ajax Therapeutics

New York City, NY, US

Founder & CEO· C-Suite · Management
Crosstrees Medical
Crosstrees Medical

Boulder, CO, US

Board Member· Board
Nora Therapeutics
Nora Therapeutics

Palo Alto, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Martin Vogelbaum's Career

Cara Therapeutics
Cara Therapeutics

Stamford, CT, US

Board Member· Board
Ajax Therapeutics
Ajax Therapeutics
Series D$40M152019New York City, NY, US
Founder & CEO· C-Suite · Management

Leadership at Ajax Therapeutics

Scott PlatshonScott PlatshonBoard Member
Ramy FaridRamy FaridBoard Member

Similar to Ajax Therapeutics

Ajax HealthAjax HealthMenlo Park, CA, USBiotech Drugsest. 2017Ajax HealthMenlo Park, CA, US · est. 2017

Ajax Health LLC: A capital provider developing and manufacturing biotech drugs.

Series C · $315M31
Adcentrx TherapeuticsAdcentrx TherapeuticsSan Diego, CA, USTherapeuticsest. 2021Adcentrx TherapeuticsSan Diego, CA, US · est. 2021

Adcentrx Therapeutics: Pioneering protein conjugate therapeutics for cancer and life-threatening diseases.

Series A · $101M31
Aether TherapeuticsAether TherapeuticsAustin, TX, USPharmaceuticalsest. 2022Aether TherapeuticsAustin, TX, US · est. 2022

Austin-based Aether Therapeutics develops pharmaceuticals to treat addiction and withdrawal symptoms.

Series A · $4.1M5
Accent TherapeuticsAccent TherapeuticsLexington, MA, USDrug Developmentest. 2017Accent TherapeuticsLexington, MA, US · est. 2017

Accent Therapeutics, a NY-based biopharmaceutical company, specializes in developing inhibitory molecule drugs.

Series C · $178M69
Crosstrees Medical
Crosstrees Medical
Series B$3.5M302003Boulder, CO, US
Board Member· Board

Leadership at Crosstrees Medical

Steve HochbergSteve HochbergBoard Member
Tom AfzalTom AfzalBoard Member
Dr Hansen A YuanDr Hansen A YuanBoard Member
Nora Therapeutics
Nora Therapeutics
Series B$36.8M312007Palo Alto, CA, US
Board Member· Board

Leadership at Nora Therapeutics

Bryant FongBryant FongBoard Member
Jeffrey TongJeffrey TongBoard Member
Chris McClainChris McClainFounder
David SchnellDavid SchnellBoard Member
Don HaydenDon HaydenBoard Member
Anupam DalalAnupam DalalBoard Member

Similar to Nora Therapeutics

Novoron BioscienceNovoron BioscienceSan Diego, CA, USPharmaceutical Therapiesest. 2014Novoron BioscienceSan Diego, CA, US · est. 2014

Biotech firm specializing in pharmaceutical therapies for central nervous system regeneration.

Seed · $13.8M5
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Granata BioGranata BioDuxbury, MA, USBiopharmaceuticalsest. 2018Granata BioDuxbury, MA, US · est. 2018

Fertility biotech firm specializing in innovative solutions for patients.

Series A · $14.1M5
Novita TherapeuticsNovita TherapeuticsOlathe, KS, USDrug Development, Medical Devicesest. 2019Novita TherapeuticsOlathe, KS, US · est. 2019

Novita Therapeutics: A Kansas-based biopharmaceutical firm specializing in early-stage drug and device development.

Series B · $7.7M5

Martin Vogelbaum's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Martin Vogelbaum

Adam MalamedAdam MalamedCEO · Sanctuary WealthLarry MendelsohnLarry MendelsohnBoard Member · Great AjaxJoel S. MarcusJoel S. MarcusBoard Member · BioHealth InnovationRobert WeigleRobert WeigleBoard Member · Tenon MedicalRonald MartellRonald MartellBoard Member · Indapta TherapeuticsMichael J HigginsMichael J HigginsBoard Member · Pulmatrix